about
A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the futureManaging population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.Policy decision options during the first 5 years following certification of polio eradication.Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmissionAn economic analysis of poliovirus risk management policy options for 2013-2052Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needsCharacterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.Eradication versus control for poliomyelitis: an economic analysis.The potential impact of expanding target age groups for polio immunization campaigns.Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.Expert review on poliovirus immunity and transmission.Preeradication vaccine policy options for poliovirus infection and disease control.Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.Poliovirus vaccination during the endgame: insights from integrated modeling.Economic analysis of the global polio eradication initiative.Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.The costs of future polio risk management policies.Retrospective cost-effectiveness analyses for polio vaccination in the United States.Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.Modeling the dynamics of oral poliovirus vaccine cessation.
P50
Q28261403-2CA6237D-6ACB-48A9-B65D-18F724B296CBQ30204646-BB750EF8-20FA-4B47-824E-DD11CDAA633EQ33873406-7B7EAA2E-A5EC-4A0F-B3E6-9A3AA58A1A53Q34305452-F551EB31-485B-40B0-AD5D-9AF83AA04B97Q34632088-4A452780-3BF5-46F5-8508-BE853859BCAFQ35131980-25C8D80E-2DFB-47B6-9125-682D19E42F4AQ35603330-3E370784-442C-4981-9F01-C3BCDFFB38ACQ35639738-FFF99290-6ED9-4E79-A8EE-3E4D887E9BA5Q35662053-7E14CE06-3D94-4676-BF93-F1595677E7BBQ35779660-5818B258-710C-45D4-9AEC-C7B944555BB1Q35779733-0CE2E501-2702-4825-B9BE-99CFB7A49CD2Q35779856-655BF113-2AC0-41A1-B095-1FF0D8ADF50DQ35787304-ADC96568-471B-4EEC-93A3-0828B11354A9Q35787331-802E7377-41B1-4795-BE6B-F19A48A245BAQ35968325-8C5FC36F-452C-48B6-AD14-137BF5560219Q36031421-B4CC2F4A-1D0D-4FF6-925C-47F23870C705Q36035498-1805D923-CE53-453A-B450-3C91A3C35C95Q36797654-44DF5E3A-F19F-4DF3-B482-B4BFA93315E3Q37568832-E01A32D1-310B-4C9E-B3D2-1FC7364A5D13Q38006994-3956ED8A-9EBB-437C-A466-917E4387EF31Q38026922-0FAE629D-8518-481A-BCD8-99DB776732DDQ38086593-202B0A77-0DC4-4451-9C74-39D536D20726Q38087428-544EB7FE-9E12-49CD-A36E-6DDE916ECCB7Q38095550-F183B054-71E0-434A-9B97-EF0E02CA0C8BQ38168905-39653EC9-1492-4E06-9FB8-960287A15F1AQ38573897-77D04BCC-4551-44C7-B0EB-7A7991DC31DFQ38661101-0E7574DF-8C69-448F-A8E4-F8A60FAFA182Q38729183-9D6FE49F-940B-4C92-AD0B-C26F731394E6Q38796753-8653E1B6-D50E-460D-80C8-FE3142CDD9D2Q39112948-664EEB6D-D964-4709-AB0B-B14D3C9AC4D4Q39258694-89DCAD5F-50BC-49EC-8E8C-F63578A70C47Q39823159-DA738767-48AD-42A7-AC48-45E2295B2185Q40071746-9E2080BA-2E7C-43A2-BCD5-429CAFBFC03AQ40071754-A4DD3BEA-7B5B-49C1-9C2F-9367DBE5438AQ40258086-47E31775-8EF0-4CD6-A945-ED4929147E2EQ40258094-94C2F6C3-7543-4787-BB7F-74652C5054BEQ41692843-823CE52A-38F5-462E-948F-F1953C06B2BEQ41700694-3CE11246-D973-4A89-B549-FCBEC9F9C109Q42183578-2110C514-E976-4F09-AFA0-68114653605AQ42183580-3888D778-63B9-4B8E-8D83-F5CEE98C497B
P50
description
researcher
@en
wetenschapper
@nl
name
Radboud J Duintjer Tebbens
@en
Radboud J Duintjer Tebbens
@nl
type
label
Radboud J Duintjer Tebbens
@en
Radboud J Duintjer Tebbens
@nl
prefLabel
Radboud J Duintjer Tebbens
@en
Radboud J Duintjer Tebbens
@nl
P31
P496
0000-0002-9645-7595